<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00417534</url>
  </required_header>
  <id_info>
    <org_study_id>214841</org_study_id>
    <nct_id>NCT00417534</nct_id>
  </id_info>
  <brief_title>Genetic Predisposition of Coronary Artery Disease -- The COROGENE-Study</brief_title>
  <official_title>Genetic Predisposition of Coronary Artery Disease in Patients Verified With Coronary Angiogram The COROGENE-Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University</source>
  <brief_summary>
    <textblock>
      The aim of this study is to identify genetic loci,or gene variations contributing to
      inflammation and to the development of CHD. We will compare coronary angiogram results to
      genetic findings within coronary artery disease patients and in patients with normal
      coronaries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary artery disease (CAD) is a chronic inflammatory disease, progression of which may be
      accelerated by immunological mechanisms. Genes involved in regulation of inflammation and
      protection against infectious agents may affect picture of the disease . Major
      Histocompatibility Complex (MHC) region carries genes involved in innate and adaptive
      immunity and inflammation. We have for the first time, identified genetic factors located in
      HLA region, showing several fold risk for disease predisposition likely forming an important
      component to explain the high incidence of coronary heart disease in the Finnish population.

      The aim of this study is to rerun our preliminary results, and further identify genetic loci,
      or gene variations contributing to the development of CHD. The strategy is to collect
      altogether 5000 patients assigned to coronary angiogram in Helsinki University Central
      Hospital. We will compare the angiogram results to genetic findings first in patients with
      normal coronaries, and in patients with different stages of CHD. Secondly we will compare
      phenotypic changes in inflammation and try to find out if the phenotype differs in different
      genotypes. Thirdly we will collect patients from hospital discharge registry, and compare
      mortality and morbidity results in different gene groups.

      Finally, we aim to record echocardiograms of the aortic valves in altogether 3500 consecutive
      patients undergoing coronary angiography. We try to identify genetic loci and gene variations
      contributing to the fibrosis and calcification of the aortic valve.

      The results of the study provide a possibility to develop a gene test to recognize patients
      at risk at its early stage, and needing for preventive medicine.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2006</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Longitudinal, Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Inflammation</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient assigned to coronary angiogram

        Exclusion Criteria:

          -  Inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juha P Sinisalo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital, Division of Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juha P Sinisalo, MD, PhD</last_name>
    <phone>+35894711</phone>
    <email>juha.sinisalo@hus.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helsinki University Central Hospital, Division of Cardiology</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juha P Sinisalo, MD, PhD</last_name>
      <phone>+35894711</phone>
      <email>juha.sinisalo@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Juha P Sinisalo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005 Apr 21;352(16):1685-95. Review.</citation>
    <PMID>15843671</PMID>
  </reference>
  <reference>
    <citation>Sinisalo J, Mattila K, Valtonen V, Anttonen O, Juvonen J, Melin J, Vuorinen-Markkola H, Nieminen MS; Clarithromycin in Acute Coronary Syndrome Patients in Finland (CLARIFY) Study Group. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation. 2002 Apr 2;105(13):1555-60.</citation>
    <PMID>11927522</PMID>
  </reference>
  <reference>
    <citation>Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, Danesh J. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet. 2006 Feb 25;367(9511):651-8. Review.</citation>
    <PMID>16503463</PMID>
  </reference>
  <reference>
    <citation>Swanberg M, Lidman O, Padyukov L, Eriksson P, Akesson E, Jagodic M, Lobell A, Khademi M, Börjesson O, Lindgren CM, Lundman P, Brookes AJ, Kere J, Luthman H, Alfredsson L, Hillert J, Klareskog L, Hamsten A, Piehl F, Olsson T. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet. 2005 May;37(5):486-94. Epub 2005 Apr 10.</citation>
    <PMID>15821736</PMID>
  </reference>
  <reference>
    <citation>Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Mäkelä PH, Huttunen JK, Valtonen V. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988 Oct 29;2(8618):983-6.</citation>
    <PMID>2902492</PMID>
  </reference>
  <reference>
    <citation>Lusis AJ, Mar R, Pajukanta P. Genetics of atherosclerosis. Annu Rev Genomics Hum Genet. 2004;5:189-218. Review.</citation>
    <PMID>15485348</PMID>
  </reference>
  <reference>
    <citation>Paavonen KJ, Chapman H, Laitinen PJ, Fodstad H, Piippo K, Swan H, Toivonen L, Viitasalo M, Kontula K, Pasternack M. Functional characterization of the common amino acid 897 polymorphism of the cardiac potassium channel KCNH2 (HERG). Cardiovasc Res. 2003 Sep 1;59(3):603-11.</citation>
    <PMID>14499861</PMID>
  </reference>
  <reference>
    <citation>Ozaki K, Ohnishi Y, Iida A, Sekine A, Yamada R, Tsunoda T, Sato H, Sato H, Hori M, Nakamura Y, Tanaka T. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet. 2002 Dec;32(4):650-4. Epub 2002 Nov 11. Erratum in: Nat Genet. 2003 Jan;33(1):107..</citation>
    <PMID>12426569</PMID>
  </reference>
  <verification_date>December 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2006</study_first_submitted>
  <study_first_submitted_qc>December 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2007</study_first_posted>
  <last_update_submitted>July 2, 2007</last_update_submitted>
  <last_update_submitted_qc>July 2, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2007</last_update_posted>
  <keyword>Coronary Disease</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Genetics</keyword>
  <keyword>HLA Antigens</keyword>
  <keyword>Aortic Valve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

